Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Secukinumab bij PsA en SA
jul 2017 | Arthritis psoriatica
nov 2022 | Psoriasis
nov 2020
okt 2020
aug 2020 | RA, SLE